{"id":223681,"date":"2025-05-12T10:15:00","date_gmt":"2025-05-12T14:15:00","guid":{"rendered":"https:\/\/ibkrcampus.com\/campus\/?p=223681"},"modified":"2025-05-13T03:41:40","modified_gmt":"2025-05-13T07:41:40","slug":"orbisa-on-smmt","status":"publish","type":"post","link":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/","title":{"rendered":"Orbisa on SMMT"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">EquiLend Data &amp; Analytics&nbsp;identifies&nbsp;Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month. With&nbsp;utilization&nbsp;approaching 78.98% and elevated borrow fees, short sellers are facing mounting pressure as positive clinical trial results drive momentum. This $24.5B biotech powerhouse has broken key technical resistance levels, potentially triggering a significant short covering rally in the coming weeks.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-overview\">Company Overview<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel antibiotics for the treatment of infectious diseases. The company\u2019s lead product candidate is\u00a0ridinilazole, which is being developed for the treatment of\u00a0Clostridioides\u00a0difficile infection (CDI).\u00a0Summit is also developing a pipeline of novel mechanism antibiotics for the treatment of serious bacterial infections.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"845\" height=\"425\" data-src=\"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/Screenshot-2025-05-12-100313.png\" alt=\"Company Overview\" class=\"wp-image-223683 lazyload\" data-srcset=\"https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/Screenshot-2025-05-12-100313.png 845w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/Screenshot-2025-05-12-100313-700x352.png 700w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/Screenshot-2025-05-12-100313-300x151.png 300w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/Screenshot-2025-05-12-100313-768x386.png 768w\" data-sizes=\"(max-width: 845px) 100vw, 845px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 845px; aspect-ratio: 845\/425;\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-catalyst\">CATALYST<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Summit Therapeutics recently announced positive results from its Phase 3 clinical trial for&nbsp;ivonescimab, a novel PD-1\/VEGF bispecific antibody for the treatment of non-small cell lung cancer (NSCLC). The trial&nbsp;demonstrated&nbsp;a statistically significant improvement in progression-free survival compared to standard of care. This breakthrough has significantly increased investor interest in the company, potentially triggering a short squeeze as short sellers reassess their positions.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-squeeze-analysis\">SQUEEZE ANALYSIS<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Summit Therapeutics (SMMT) currently has a short squeeze score of 66, which&nbsp;represents&nbsp;a significant increase of 43.0 points from last month.&nbsp;Our&nbsp;proprietary EquiLend Short Squeeze Score metric, which ranges from 0 to 100, measures the likelihood of a potential short squeeze by analyzing factors such as short interest, borrowing costs and price momentum. A higher score&nbsp;indicates&nbsp;increased probability of a short squeeze event.&nbsp;This dramatic rise in short squeeze score&nbsp;indicates&nbsp;growing pressure on short sellers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The stock\u2019s&nbsp;utilization&nbsp;rate of 78.98% is approaching critical levels, suggesting that available shares for borrowing are becoming scarce.&nbsp;Utilization&nbsp;measures the percentage of available shares that are currently being borrowed&nbsp;relative&nbsp;to the total lendable inventory, with higher rates&nbsp;indicating&nbsp;potential supply constraints in the securities lending market.&nbsp;Combined with&nbsp;elevated&nbsp;borrowing fees&nbsp;compared to historical averages, short sellers are facing increasing costs to&nbsp;maintain&nbsp;their positions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The recent positive clinical trial results have driven strong buying pressure, creating a potential trigger for a short squeeze. As the stock price continues to rise, short sellers may be forced to&nbsp;cover their positions, further accelerating the upward price movement.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technical-analysis\">TECHNICAL ANALYSIS<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Summit Therapeutics Inc.\u2019s&nbsp;stock&nbsp;has broken&nbsp;above its 50-day and 200-day moving averages, confirming a bullish trend. Volume has been increasing on&nbsp;up&nbsp;days, suggesting strong buying interest. The Relative Strength Index (RSI) is&nbsp;above&nbsp;70,&nbsp;indicating&nbsp;strong momentum&nbsp;and&nbsp;overbought conditions but not yet at extreme levels that would signal an imminent reversal.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1100\" height=\"683\" data-src=\"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT-1100x683.jpeg\" alt=\"Summit Therapeutics Inc.\u2019s stock \" class=\"wp-image-223684 lazyload\" data-srcset=\"https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT-1100x683.jpeg 1100w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT-700x435.jpeg 700w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT-300x186.jpeg 300w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT-768x477.jpeg 768w, https:\/\/ibkrcampus.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg 1200w\" data-sizes=\"(max-width: 1100px) 100vw, 1100px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1100px; aspect-ratio: 1100\/683;\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\">CONCLUSION<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Summit Therapeutics (SMMT) presents a compelling short squeeze opportunity due to its high and rapidly increasing short squeeze score of 66 (up 43.0 points in the last month), elevated&nbsp;utilization&nbsp;rate of 78.98% and recent positive clinical trial results serving as a catalyst.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The combination of fundamental catalysts, technical breakout and deteriorating securities lending metrics suggests that short sellers are under significant pressure. Traders looking to capitalize on potential short squeeze opportunities should monitor SMMT closely, particularly for increases in trading volume and acceleration in price movement, which&nbsp;could signal the beginning of a more pronounced squeeze.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Contact us at&nbsp;<a href=\"https:\/\/equilend.com\/services\/equilend-short-squeeze-score\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>https:\/\/equilend.com\/services\/equilend-short-squeeze-score\/<\/strong><\/a>&nbsp;to find out how you can leverage EquiLend\u2019s Short Squeeze Score today.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bloomberg Terminal users can subscribe to EquiLend\u2019s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA &lt;GO&gt; or clicking the following link:&nbsp;<a href=\"https:\/\/blinks.bloomberg.com\/screens\/apps%20orbisa\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/on.equilend.com\/bloomberg-terminal-page<\/a><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8212;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Originally Posted April 28, 2025 &#8211; <a href=\"https:\/\/orbisa.com\/insight\/orbisa-on-smmt\/\">Orbisa on SMMT<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EquiLend Data &amp; Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month. <\/p>\n","protected":false},"author":186,"featured_media":223684,"comment_status":"open","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[6,8,9,20,22,26,3],"tags":[19435,19436,19434,521,19433],"contributors-categories":[15990],"class_list":["post-223681","post","type-post","status-publish","format-standard","has-post-thumbnail","category-north-america","category-region","category-securities","category-short-selling","category-stocks","category-text-articles","category-traders-insight","tag-biotech-breakout","tag-bullish-technicals","tag-clinical-trial-results","tag-securities-lending","tag-short-squeeze-candidate","contributors-categories-orbisa"],"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.9 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Orbisa on SMMT | Traders&#039; Insight<\/title>\n<meta name=\"description\" content=\"EquiLend Data &amp; Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/223681\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orbisa on SMMT | IBKR Campus US\" \/>\n<meta property=\"og:description\" content=\"EquiLend Data &amp; Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/\" \/>\n<meta property=\"og:site_name\" content=\"IBKR Campus US\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-12T14:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-13T07:41:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"745\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Contributor Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Contributor Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t    \"@context\": \"https:\\\/\\\/schema.org\",\n\t    \"@graph\": [\n\t        {\n\t            \"@type\": \"NewsArticle\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#article\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/\"\n\t            },\n\t            \"author\": {\n\t                \"name\": \"Contributor Author\",\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/e823e46b42ca381080387e794318a485\"\n\t            },\n\t            \"headline\": \"Orbisa on SMMT\",\n\t            \"datePublished\": \"2025-05-12T14:15:00+00:00\",\n\t            \"dateModified\": \"2025-05-13T07:41:40+00:00\",\n\t            \"mainEntityOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/\"\n\t            },\n\t            \"wordCount\": 647,\n\t            \"commentCount\": 0,\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/05\\\/SMMT.jpeg\",\n\t            \"keywords\": [\n\t                \"biotech breakout\",\n\t                \"bullish technicals\",\n\t                \"clinical trial results\",\n\t                \"securities lending\",\n\t                \"short squeeze candidate\"\n\t            ],\n\t            \"articleSection\": [\n\t                \"North America\",\n\t                \"Region\",\n\t                \"Securities\",\n\t                \"Short Selling\",\n\t                \"Stocks\",\n\t                \"Text Articles\",\n\t                \"Traders' Insight\"\n\t            ],\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"CommentAction\",\n\t                    \"name\": \"Comment\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#respond\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"WebPage\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/\",\n\t            \"name\": \"Orbisa on SMMT | IBKR Campus US\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\"\n\t            },\n\t            \"primaryImageOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#primaryimage\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/05\\\/SMMT.jpeg\",\n\t            \"datePublished\": \"2025-05-12T14:15:00+00:00\",\n\t            \"dateModified\": \"2025-05-13T07:41:40+00:00\",\n\t            \"description\": \"EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month.\",\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"ReadAction\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"ImageObject\",\n\t            \"inLanguage\": \"en-US\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/traders-insight\\\/securities\\\/short-selling\\\/orbisa-on-smmt\\\/#primaryimage\",\n\t            \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/05\\\/SMMT.jpeg\",\n\t            \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/05\\\/SMMT.jpeg\",\n\t            \"width\": 1200,\n\t            \"height\": 745,\n\t            \"caption\": \"Summit Therapeutics Inc.\u2019s stock\"\n\t        },\n\t        {\n\t            \"@type\": \"WebSite\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t            \"name\": \"IBKR Campus US\",\n\t            \"description\": \"Financial Education from Interactive Brokers\",\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t            },\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"SearchAction\",\n\t                    \"target\": {\n\t                        \"@type\": \"EntryPoint\",\n\t                        \"urlTemplate\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/?s={search_term_string}\"\n\t                    },\n\t                    \"query-input\": {\n\t                        \"@type\": \"PropertyValueSpecification\",\n\t                        \"valueRequired\": true,\n\t                        \"valueName\": \"search_term_string\"\n\t                    }\n\t                }\n\t            ],\n\t            \"inLanguage\": \"en-US\"\n\t        },\n\t        {\n\t            \"@type\": \"Organization\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\",\n\t            \"name\": \"Interactive Brokers\",\n\t            \"alternateName\": \"IBKR\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t            \"logo\": {\n\t                \"@type\": \"ImageObject\",\n\t                \"inLanguage\": \"en-US\",\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\",\n\t                \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t                \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t                \"width\": 669,\n\t                \"height\": 669,\n\t                \"caption\": \"Interactive Brokers\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\"\n\t            },\n\t            \"publishingPrinciples\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/about-ibkr-campus\\\/\",\n\t            \"ethicsPolicy\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/cyber-security-notice\\\/\"\n\t        },\n\t        {\n\t            \"@type\": \"Person\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/e823e46b42ca381080387e794318a485\",\n\t            \"name\": \"Contributor Author\",\n\t            \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/author\\\/contributor-author\\\/\"\n\t        }\n\t    ]\n\t}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Orbisa on SMMT | Traders' Insight","description":"EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/223681\/","og_locale":"en_US","og_type":"article","og_title":"Orbisa on SMMT | IBKR Campus US","og_description":"EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month.","og_url":"https:\/\/www.interactivebrokers.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/","og_site_name":"IBKR Campus US","article_published_time":"2025-05-12T14:15:00+00:00","article_modified_time":"2025-05-13T07:41:40+00:00","og_image":[{"width":1200,"height":745,"url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","type":"image\/jpeg"}],"author":"Contributor Author","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Contributor Author","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#article","isPartOf":{"@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/"},"author":{"name":"Contributor Author","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/e823e46b42ca381080387e794318a485"},"headline":"Orbisa on SMMT","datePublished":"2025-05-12T14:15:00+00:00","dateModified":"2025-05-13T07:41:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/"},"wordCount":647,"commentCount":0,"publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","keywords":["biotech breakout","bullish technicals","clinical trial results","securities lending","short squeeze candidate"],"articleSection":["North America","Region","Securities","Short Selling","Stocks","Text Articles","Traders' Insight"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/","url":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/","name":"Orbisa on SMMT | IBKR Campus US","isPartOf":{"@id":"https:\/\/ibkrcampus.com\/campus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#primaryimage"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","datePublished":"2025-05-12T14:15:00+00:00","dateModified":"2025-05-13T07:41:40+00:00","description":"EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its short squeeze score surging 43.0 points to 66 in just one month.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibkrcampus.com\/campus\/traders-insight\/securities\/short-selling\/orbisa-on-smmt\/#primaryimage","url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","contentUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","width":1200,"height":745,"caption":"Summit Therapeutics Inc.\u2019s stock"},{"@type":"WebSite","@id":"https:\/\/ibkrcampus.com\/campus\/#website","url":"https:\/\/ibkrcampus.com\/campus\/","name":"IBKR Campus US","description":"Financial Education from Interactive Brokers","publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibkrcampus.com\/campus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ibkrcampus.com\/campus\/#organization","name":"Interactive Brokers","alternateName":"IBKR","url":"https:\/\/ibkrcampus.com\/campus\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/","url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","contentUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","width":669,"height":669,"caption":"Interactive Brokers"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/"},"publishingPrinciples":"https:\/\/www.interactivebrokers.com\/campus\/about-ibkr-campus\/","ethicsPolicy":"https:\/\/www.interactivebrokers.com\/campus\/cyber-security-notice\/"},{"@type":"Person","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/e823e46b42ca381080387e794318a485","name":"Contributor Author","url":"https:\/\/www.interactivebrokers.com\/campus\/author\/contributor-author\/"}]}},"jetpack_featured_media_url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/05\/SMMT.jpeg","_links":{"self":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/223681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/users\/186"}],"replies":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/comments?post=223681"}],"version-history":[{"count":0,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/223681\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/media\/223684"}],"wp:attachment":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/media?parent=223681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/categories?post=223681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/tags?post=223681"},{"taxonomy":"contributors-categories","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/contributors-categories?post=223681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}